UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2019

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F =Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation: Canonic Company Introduction – April 2019.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

By: /s/ Dorit Kreiner ——————————————

Dorit Kreiner Chief Financial Officer

Date: April 15, 2019

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	A Slide Presentation: Canonic Company Introduction – April 2019.
	4

Safe harbor

This presentation contains "forward-loking to future events, and ve may from time to time make other statements, regarding our outlock or expectations for future finacial or ceating results and on affecting bygent the minister of will that in the inter considered there coloridation in the use of vier looking stateners and fanticipate, " should," "planned," intend" and "potential" or words of similar meaning. For these statems the protection of the safe harbor for forward-loking statements contained in the PSLRA.

Such statements an based on curent expections and asumptions, describe opinions about foture event, involve entain risk and uncertainted which are difficult to pedict and are not guarantees of future performance or achievenents, and trents in the futur of Evogene may differ materially from what is expressed or implied by such forvard-looking streets many of which are beyond Evogene's contol, including, without limitation, those described in grater detail in our Periodical and Anual Reports, including our F-1, Amual Report on Form 20-F and in other information we file and furnish with the Irae Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attribution on our betalf are expressy qualifed in their entirely by the previous statements. Exept for any obigations to disclose information as required by applicable seurities any obligation or commitment to update any information on this presentation or to publicy release the results of any statements that may be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained here not constitute a prospects or other of form part of any invitation of fer to sell, or any solication of any invitation of offer to purchase or subscribes of Evogene or any other entity, nor shall the information or any part of it of the fast of its distribution form the basis of or relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the reference purposs only. Such use should not be construed as an endorsement of the products or services of Evogene.

CANONIC

About us

Canonic is a fully owned subsidiary of Evogene Ltd* targeted to develop medical grade cannabis through a revolutionary approach utilizing disruptive genomic, big data and artificial intelligence technological platform
Focused on improving yield and metabolite stability, and cannabis varieties for the main medical indications: PTSD, severe chronic pain and cancer
Harnessing more than 10 years of Evogene's experience and reputation in plant genomics, including collaborations with international ag companies - Bayer, Corteva, Monsanto, Syngenta, and others
Exclusive access to Evogene's CPB platform technology, IP and infrastructure for its cannabis R&D program including regulatory approvals for the establishment of a cannabis research facility

* Evogene Ltd. – Publicly traded in TASE and NASDAQ (EVGN); Cash balance of > \$50 Million (31/12/2018)

CANONIC

Agenda

Mission, Market & Challenges

Solution & Technology

Target Products & Business Plan

Assets & Capabilities

Summary

-- CANONİC

To develop and bring to market medical grade cannabis through a revolutionary genomic approach

The cannabis market

Vast medical applications

CANONIC

Source: Leafly Holdings

Source: New frontier data (US only)

KEY F

METABOLITE YIELD

Low yields burden growers and patients with higher product and manufacturing costs.

\$980 per pound Production cost

Relative St Dev (%)

14.3

\$1,869 Annual average expenditure of medical cannabis user

VARIETY STABILITY

Substantial variations within varieties produce inconsistent products that have become unreliable as a medical treatment.

MEDICAL TAILORED PRODUCTS

Specific medical indications require tailored metabolite profiles. To date, breeding mainly pushed THC levels.

43.2

21 1

23.1

CHALLENGES

CANONIC